11β-Hydroxysteroid dehydrogenase-1 as a therapeutic target for metabolic diseases

Bibliography

• ZIMMET PZ, ALBERTI KG, SHAW J: Global and societal implications of the diabetes epidemic. Nature (2001) 414:782–787.
   PubMed Web of Science ®Google Scholar
• ROSS SA, GULVE EA, WANG M: Chemistry and biochemistry of Type 2 diabetes. Chem. Rev. (2004) 104(3):1255–1282.
   PubMed Web of Science ®Google Scholar
• ••An extensive review on the manybiochemical pathways involved in Type 2 diabetes.
   Google Scholar
• WAJCHENBERG BL: Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocrine Rev. (2000) 21(6):697–738.
   PubMed Web of Science ®Google Scholar
• SKYLER JS: Diabetes mellitus: pathogenesis and treatment strategies. J. Med. Chem. (2004) 47(17):4113–4117.
   PubMed Web of Science ®Google Scholar
• •A review that summarises many of the current treatment strategies.
   Google Scholar
• RASK E, OLSSON T, SODERBERG S et al.: Tissue-specific dysregulation of cortisol metabolism in human obesity. J. Clin. EndocrinoL Metab. (2001) 86(3):1418–1421.
   PubMed Web of Science ®Google Scholar
• DEFRONZO RA: Pathogenesis of Type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev. (1997) 5:177–269.
   Google Scholar
• NOBEL S, ABRAHMSEN L, OPPERMANN U: Metabolic conversion as a pre-receptor control mechanism for lipophilic hormones. Euro. J. Biochem. (2001) 268(15):4113–4125.
   PubMedGoogle Scholar
• FRIEDMAN JE, YUN JS, PATEL YM, MCGRANE MM, HANSON RW: Glucocorticoids regulate the induction of phosphoenolpyruvate carboxykinase (GTP) gene transcription during diabetes. J. Biol. Chem. (1993) 268(17):12952–12957.
   PubMed Web of Science ®Google Scholar
• HANSON RW, RESHEF L: Regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression. Ann. Rev. Biochem. (1997) 66:581–611.
   PubMed Web of Science ®Google Scholar
• SECKL JR, WALKER BR: Minireview: 1113-hydroxysteroid dehydrogenase Type 1 - a tissue-specific amplifier of glucocorticoid action. Endocrinology (2001) 142(4):1371–1376.
   PubMed Web of Science ®Google Scholar
• STULNIG TM, WALDHAUSL W: 1113-hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes. Diabetologia (2004) 47(1):1–11.
   PubMed Web of Science ®Google Scholar
• ••A key review covering the literature supporting a link between 1113HSD1 and obesity.
   Google Scholar
• KOTELEVTSEV Y, HOLMES MC, BURCHELL A et aL:1113-hydroxysteroid dehydrogenase Type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc. Natl. Acad. Sci. USA (1997) 94(20:14924–14929.
   PubMedGoogle Scholar
• MASUZAKI H, PATERSON J, SHINYAMA H et aL: A transgenic model of visceral obesity and the metabolic syndrome. Science (2001) 294(5549):2166–2170.
   PubMed Web of Science ®Google Scholar
• WALKER BR, SECKL JR: 1113-Hydroxysteroid dehydrogenase Type 1 as a novel therapeutic target in metabolic and neurodegenerative disease. Expert Opin. Ther. Targets (2003) 7(6):771–783.
   PubMed Web of Science ®Google Scholar
• ••A key review that covers much of the workrelating 1113HSD1 to Type 2 diabetes.
   Google Scholar
• PAVLOVA SI, UTESHEV BS, SERGEEVAV: Licorice root: possible mechanisms of antioxidant, anti-carcinogen, and anti-tumor properties. Pharma. Chem. J. (2003) 37(6):314–317.
   Google Scholar
• HATTORI M, SAKAMOTO T, KOBASHI K, NAMBA T: Metabolism of glycyrrhizin by human intestinal flora. Planta medica (1983) 48(1):38–42.
   PubMed Web of Science ®Google Scholar
• HATTORI M, SAKAMOTO T, YAMAGISHI T et aL: Metabolism of glycyrrhizin by human intestinal flora. II. Isolation and characterization of human intestinal bacteria capable of metabolizing glycyrrhizin and related compounds. Chem. Pharm. Bull. (1985) 33(1):210–217.
   Google Scholar
• HULT M, JORNVALL H, OPPERMANN UC: Selective inhibition of human Type 1 1113-hydroxysteroid dehydrogenase by synthetic steroids and xenobiotics. FEBS Letts. (1998) 441(1):25–28.
   PubMed Web of Science ®Google Scholar
• WALKER BR, CONNACHER AA, LINDSAY RM, WEBB DJ, EDWARDS CRW: Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J. Clin. Endocrin. Metab. (1995) 80(11):3155–3159.
   PubMed Web of Science ®Google Scholar
• ANDREWS RC, ROOYACKERS 0, WALKER BR: Effects of the 1113-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with Type 2 diabetes.J Clin. Endocrin. Metab. (2003) 88(1):285–291.
   Google Scholar
• BARF T, VALLGRDA J, EMOND R et aL: Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 1113-hydroxysteroid dehydrogenase Type 1. J. Med. Chem. (2002) 45(18):3813–3815.
   Google Scholar
• •One of the first reports of a non-steroidal inhibitor that is a selective for 1113HSD1.
   Google Scholar
• ALBISTON AL, OBEYESEKERE VR, SMITH RE, KROZOWSKI ZS: Cloning and tissue distribution of the human 1113-hydroxysteroid dehydrogenase Type 2 enzyme. MoL Cell. EndocrinoL (1994) 105(2):R11–R17.
   Web of Science ®Google Scholar
• AGARWAL AK, MUNE T, MONDER C, WHITE PC: NAD*-dependent isoform of 1113-hydroxysteroid dehydrogenase. Cloning and characterization of cDNA from sheep kidney. J. Biol. Chem. (1994) 269(42):25959–25962.
   Google Scholar
• KOTELEVTSEV Y, BROWN RW, FLEMING S et al: Hypertension in mice lacking 1113-hydroxysteroid dehydrogenase Type 2.j CAn. Invest. (1999) 103(5):683–689.
   Google Scholar
• CHROUSOS GP: Is 1113-hydroxysteroid dehydrogenase Type 1 a good therapeutic target for blockade of glucocorticoid actions? Proc. Natl Acad. Sci. USA (2004) 101(17):6329–6330.
   PubMed Web of Science ®Google Scholar
• OLSON S, BALKOVEC J, GAO Y-D et al: Selective inhibitors of 1113-hydroxysteroid dehydrogenase Type 1. adamantyl triazoles as pharmacological agents for the treatment of metabolic syndrome. Keystone Symposia: Molecular Controls of Adipogenesis and Obesity Alberta, Canada (2004) 329.
   Google Scholar
• HERMANOWSKI-VOSATKA A, MUNDT S, NUNES C et ed.:1113HSD1 inhibition ameliorates metabolic syndrome in mice. Keystone Symposia: Molecular Controls of Adipogenesis and Obesity Alberta, Canada (2004) 215.
   Google Scholar
• KURZ G, BARF T, VALLGARDA Jet aL: For mice and men? Inhibitors of 1113-hydroxysteroid dehydrogenase Type 1 with anti-diabetic potential. Drugs Fut. (2004) 29(Suppl. A):101.
   Google Scholar
• RAUZ S, CHEUNG CM: WOOD PJ et al: Inhibition of 1113-hydroxysteroid dehydrogenase Type 1 lowers intraocular pressure in patients with ocular hypertension. Q. J. Med. (2003) 96:481–90.
   Google Scholar
• HOSFIELD D, YIQIN W et ed: Conformational flexibility in crystal structures of human 1113-HSD1 provide insights into glucocorticoid interconversion and enzyme regulation. J. BioL Chem. in press.
   Google Scholar
• OGG D, BJORN E et al. The crystal structure of guinea pig 1113HSD1 provides a model for enzyme-lipid interactions. J. Biol. Chem. in press.
   Google Scholar